A recent report published in the journal PLOS Pathogens described that individuals infected with Delta variants even if vaccinated can still shed infectious SARS-CoV-2 and play a role in spreading COVID-19 to others. In order to limit transmission to the greatest extent possible, researchers at Creative Biolabs believe that infection prevention is still the essential strategy for those who have and have not received the COVID-19 vaccine.
Infectious virus titer in this study found no difference between vaccinated samples and unvaccinated samples. A further conclusion was drawn that Ct value in breakthrough infection is not strongly affected by vaccine product, age, or sex, which to some degree brings new challenges to existing SARS-CoV-2 vaccines.
"We notice that the team evaluated the presence of an infectious virus and observed the presence of the cytopathic effect (CPE) over five days using an initial batch of specimens with Ct <25. Actually, SARS-CoV-2 CPE detection is an effective method to help isolate and identify viruses as well as diagnose viral infection. That's why we make SARS-CoV-2 CPE assay broadly available in our service package for COVID-19 drug and vaccine research." An expert at Creative Biolabs said.
Notwithstanding the result that people who are infected despite being vaccinated could spread SARS-CoV-2, infection prevention solutions including vaccination and non-pharmaceutical measures are still important to limit the transmission of COVID-19. Creative Biolabs is a long-standing service provider in the field of antiviral drug discovery and vaccine development and attempts to help address any challenge that researchers might face with SARS-CoV-2 vaccine development.
This company initially proposed the virus-like particle (VLP)-based vaccine development strategy in 2019 and successfully developed various SARS-CoV-2 VLP products. In addition to VLP-based vaccines, up to now, it has grown comprehensive strategies to support the design, discovery, and validation of SARS-CoV-2 vaccines, such as live attenuated and killed vaccine, recombinant subunit vaccine, and mRNA vaccine to help limit even stop the spread of infectious SARS-CoV-2.
While for people with vaccine breakthrough infections and the capability of shedding infectious SARS-CoV-2, antiviral drugs rather than infection prevention is more necessary. In terms of antiviral drug discovery, Creative Biolabs wields SARS-CoV-2 peptide microarray analysis and a series of other powerful tools, which are easy to operate, cost-effective, stable, and customizable for dissecting and researching antiviral drugs, antibodies, or inhibitors of SARS-CoV-2.
About
Creative Biolabs is a biotech company focusing on pre-clinical and basic research support. The company's comprehensive antiviral drug discovery platform can realize high-throughput screening of novel drug candidates, inhibitor discovery, neutralizing antibody development, antiviral peptide discovery, and broad-spectrum antiviral drug discovery. Its SARS-CoV-2 vaccine development platform enables global researchers to design, optimize, qualify, and evaluate different types of vaccines.
The company is offering tailored CRO services for antiviral drug and vaccine research targeting SARS-CoV-2 and its variants. For more information, see https://sars-cov-2.creative-biolabs.com/.
